Collectively, we demonstrate that tumor-intrinsic IFN-γ signaling actively regulates infiltration and function of TILs; our results support Ruxo as a potential “targeted” therapy for ICB-resistant IFNγR1KO melanoma. The gene discussed is IFNG; the disease is neoplasm.